Literature DB >> 8113987

Morphine-induced excitation of pyramidal neurons is inhibited by cholecystokinin in the CA1 region of the rat hippocampal slice.

K K Miller1, C R Lupica.   

Abstract

Opioids increase the excitability of CA1 pyramidal neurons in the hippocampus through the inhibition of gamma-aminobutyric acid release from interneurons. This can be observed extracellularly as an increase in population spike amplitude. The sulfated form of the neuropeptide cholecystokinin (CCK-8S) has been shown in a variety of in vivo models to inhibit the response to opioids. We have utilized the well-characterized hippocampal response to opioids to examine the potential interactions between morphine and the neuropeptide cholecystokinin (CCK) in vitro. Morphine (1-500 microM; EC50 = 22.1 microM, 95% confidence interval = 6.5-75.9 microM) alone caused concentration-dependent increases in CA1 population spike amplitudes that were reversible upon washout or application of the opioid antagonist naloxone (10 microM). In contrast to the morphine effect, CCK-8S (0.001-1 microM) had no effect alone on population spikes (99.1 +/- 1.6% of control, P > .05). However, when hippocampal slices were pretreated with CCK-8S (0.1-1 microM), the morphine-induced increase in population spike amplitudes was blocked in a noncompetitive, reversible manner (IC50 = 17.8 nM, 95% confidence interval = 9.5-33.7 nM). This antagonism of morphine action by CCK-8S was not seen when CCK-8S was added after the opiate had achieved its maximal effect, and was blocked completely by the application of the selective CCKB receptor antagonist PD-135, 158 (1.5 microM). The unsulfated form of CCK, unlike CCK-8S, did not antagonize the excitatory actions of morphine on population spikes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113987

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Cholecystokinin increases GABA release by inhibiting a resting K+ conductance in hippocampal interneurons.

Authors:  K K Miller; A Hoffer; K R Svoboda; C R Lupica
Journal:  J Neurosci       Date:  1997-07-01       Impact factor: 6.167

2.  Interactions between cholecystokinin and opioids in the isolated guinea-pig ileum.

Authors:  L Romanelli; M C Amico; F Mattioli; L A Morrone; P Valeri
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 3.  Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction.

Authors:  B P Roques; F Noble
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

Review 4.  Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain.

Authors:  Kaitlin C Reeves; Nikhil Shah; Braulio Muñoz; Brady K Atwood
Journal:  Front Mol Neurosci       Date:  2022-06-15       Impact factor: 6.261

5.  Cholecystokinin inhibits endocannabinoid-sensitive hippocampal IPSPs and stimulates others.

Authors:  Miranda A Karson; Kevin C Whittington; Bradley E Alger
Journal:  Neuropharmacology       Date:  2007-07-01       Impact factor: 5.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.